Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Liver bioengineering using decellularized whole-liver scaffolds

  • Pla-Palacín, I.
  • Sainz-Arnal, P.
  • Morini, S.
  • Almeida, M.
  • Baptista, P.M.
Currently, due to the progress made in the field of regenerative medicine, whole-organ bioengineering is becoming a valid alternative to cope with the shortages of organs for transplantation. In this chapter, we describe the main techniques carried out for pig liver bioengineering, which serves as an essential model for future human liver bioengineering. These include porcine whole-liver decellularization, endothelial and mesenchymal stem cell isolation, porcine ES-derived hepatoblasts, and scaffold recellularization using a bioreactor perfusion system.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Reseña (Review)

The role of extracellular matrix on liver stem cell fate: A dynamic relationship in health and disease

  • Sánchez-Romero, N.
  • Sainz-Arnal, P.
  • Pla-Palacín, I.
  • Royo Dachary, P.
  • Almeida, H.
  • Pastor, C.
  • Rubio Soto, D.
  • Chico Rodriguez, M.
  • Olmedo Arbizu, E.
  • Bengochea Martinez, L.
  • Serrano-Aulló, T.
  • Baptista, P.M.
The liver stem cell niche is a specialized and dynamic microenvironment with biomechanical and biochemical characteristics that regulate stem cell behavior. This is feasible due to the coordination of a complex network of secreted factors, small molecules, neural, blood inputs and extracellular matrix (ECM) components involved in the regulation of stem cell fate (self-renewal, survival, and differentiation into more mature phenotypes like hepatocytes and cholangiocytes). In this review, we describe and summarize all the major components that play essential roles in the liver stem cell niche, in particular, growth factor signaling and the biomechanical properties of the ECM.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Naturally-Derived Biomaterials for Tissue Engineering Applications

  • Brovold, M.
  • Almeida, J.I.
  • Pla-Palacín, I.
  • Sainz-Arnal, P.
  • Sánchez-Romero, N.
  • Rivas, J.J.
  • Almeida, H.
  • Dachary, P.R.
  • Serrano-Aulló, T.
  • Soker, S.
  • Baptista, P.M.
Naturally-derived biomaterials have been used for decades in multiple regenerative medicine applications. From the simplest cell microcarriers made of collagen or alginate, to highly complex decellularized whole-organ scaffolds, these biomaterials represent a class of substances that is usually first in choice at the time of electing a functional and useful biomaterial. Hence, in this chapter we describe the several naturally-derived biomaterials used in tissue engineering applications and their classification, based on composition. We will also describe some of the present uses of the generated tissues like drug discovery, developmental biology, bioprinting and transplantation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project)

  • Gago-Veiga, Ana Beatriz
  • López-Rodríguez, Ana Belén
  • Sánchez Jiménez, Marina
  • Iglesias Rubio, Álvaro
  • Montes, Nuria
  • Camiña Muñiz, Javier
  • Domínguez Gallego, Marta
  • Calle de Miguel, Carlos
  • Latorre, Germán
  • Rodríguez-Vico, Jaime
  • Jaimes, Alex
  • Gómez García, Andrea
  • Urtiaga, Sara
  • González Salaices, Marta
  • Dileone, Michele
  • González-García, Nuria
  • Porta-Etessam, Jesús
  • Cuadrado, María-Luz
  • Herrero San-Martín, Alejandro
  • Guerrero-Peral, Ángel-Luis
  • González-Osorio, Yesica
  • Casas-Limón, Javier
  • Sánchez-Soblechero, Antonio
  • Lozano-Ros, Alberto
  • Díaz-De-Terán, Javier
  • Portocarrero-Sánchez, Leonardo
  • Molina-Martínez, Francisco-José
  • Santos-Lasaosa, Sonia
  • Martín-Ávila, Guillermo
  • Riva, Elena
  • Fernández-Lázaro, Iris
Aim Atogepant is a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine prevention. This study primarily evaluated its effectiveness and safety in real-world clinical practice, focusing on patients with treatment-resistant migraine, defined according to the European Headache Federation (EHF) criteria as failure of at least three classes of preventive medications, including onabotulinumtoxinA or anti-CGRP monoclonal antibodies (mAbs). Methods This prospective multicentre study was conducted across 15 tertiary Headache Units in Spain. Demographic and clinical data, prior preventives, monthly headache days (MHD), monthly migraine days (MMD), and adverse events (AEs) were systematically collected at baseline, 3 months (primary endpoint), and/or 6 months (secondary endpoint). Results AimA total of 513 patients were enrolled (mean age 48 years; 88% women). The 3-month analysis included 455 patients, with median MHD decreasing from 21 (IQR 15-30) to 14 (IQR 6-30) and MMD from 14 (IQR 10-20) to 8 (IQR 3-15) (both p < 0.0001). A ≥ 50% reduction was achieved by 34% (MHD) and 29% (MMD), with ≥75% responses in 16% and 13%. Adverse events were mostly mild, mainly constipation (30%) and nausea (18%), and the 3-month discontinuation rate was 11.8%. Responders had shorter migraine chronicity, less analgesic overuse, and fewer prior preventive failures. Although prior inadequate response to anti-CGRP mAbs reduced the likelihood of improvement, it did not prevent meaningful benefit. At analysis, 151 patients had reached the 6-month visit, showing further improvement (MHD 10 [IQR 5-20]; MMD 6 [IQR 4-12]) and fewer adverse events. Conclusions Atogepant showed robust real-world effectiveness and good tolerability in a large, treatment-resistant migraine cohort, with clinically meaningful improvement at 3 months and incremental benefit in the subgroup evaluated at 6 months. Lower migraine chronicity and fewer prior preventive failures were associated with better outcomes, supporting the earlier introduction of anti-CGRP therapies in clinical practice.